Key facts
- GenXys’s last known valuation is $9.8M (Mar 2020).
- It has raised $6.0M; the latest was Seed Round ($1.6M) in Feb 2025.
- Notable investors include Creative Destruction Lab, BDC Capital, TELUS Global Ventures, Green Shield, Esplanade Healthtech Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for GenXys
- ·The full record, as it builds
Funding rounds
No funding rounds for GenXys are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GenXys
Developer of an artificial intelligence-powered platform designed to support accurate and efficient prescribing in healthcare. The company offers integrated clinical decision support, real-time formulary information, and de-identified prescribing data, enabling healthcare providers, pharmacy benefit managers, and payers to reduce administrative steps, monitor prescribing trends, and manage medication use effectively.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2014
- Employees
- 20
- Website
- genxys.com/
- Ownership
- Privately Held (backing)
GenXys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenXys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenXys in its N-PORT filings yet. We sweep new filings monthly.